The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the infl...

Full description

Bibliographic Details
Published in:	Pharmaceutics
Main Authors:	Wen Yin, Tianqi Xu, Mohamed Altai, Maryam Oroujeni, Jie Zhang, Anzhelika Vorobyeva, Olga Vorontsova, Sergey V. Vtorushin, Vladimir Tolmachev, Torbjörn Gräslund, Anna Orlova
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Subjects:	HER2 affibody molecule albumin-binding domain drug conjugate targeted therapy mertansine
Online Access:	https://www.mdpi.com/1999-4923/13/11/1974

Similar Items

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
by: Tianqi Xu, et al.
Published: (2022-02-01)

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
by: Mohamed Altai, et al.
Published: (2018-10-01)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
by: Haozhong Ding, et al.
Published: (2021-03-01)

HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution
by: Haozhong Ding, et al.
Published: (2020-04-01)

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule <sup>188</sup>Re-ZHER2:41071
by: Yongsheng Liu, et al.
Published: (2022-05-01)

Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model
by: Charles Dahlsson Leitao, et al.
Published: (2020-06-01)

Preclinical Evaluation of a New Format of <sup>68</sup>Ga- and <sup>111</sup>In-Labeled Affibody Molecule Z<sub>IGF-1R:4551</sub> for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT
by: Yongsheng Liu, et al.
Published: (2022-07-01)

Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules
by: Javad Garousi, et al.
Published: (2020-06-01)

Designing, docking and heterologous expression of an anti-HER2 affibody molecule
by: N. Salmanian Tabasi, et al.
Published: (2018-02-01)

Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein
by: Javad Garousi, et al.
Published: (2021-11-01)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody<sup>®</sup> Molecules <sup>177</sup>Lu-ABY-271 and <sup>177</sup>Lu-ABY-027: Impact of DOTA Position on ABD Domain
by: Yongsheng Liu, et al.
Published: (2021-06-01)

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules
by: Sara S. Rinne, et al.
Published: (2022-05-01)

Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy
by: Nina Eissler, et al.
Published: (2024-05-01)

Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells
by: Isabella Damiani, et al.
Published: (2021-08-01)

PLGA Nanoparticles Decorated with Anti-HER2 Affibody for Targeted Delivery and Photoinduced Cell Death
by: Victoria Olegovna Shipunova, et al.
Published: (2021-06-01)

Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer
by: Ali Alhuseinalkhudhur, et al.
Published: (2020-03-01)

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis
by: Yongsheng Liu, et al.
Published: (2022-11-01)

Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients
by: Haitao Miao, et al.
Published: (2022-05-01)

An anti-CEA affibody showing high-definition staining in human pancreatic cancer tissue sections and selective tumor targeting in vivo
by: Johan Nilvebrant, et al.
Published: (2025-11-01)

The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer
by: Cai W, et al.
Published: (2023-01-01)

<sup>89</sup>Zr-Radiolabelling of p-NCS-Bz-DFO-Anti-HER2 Affibody Immunoconjugate: Characterization and Assessment of In Vitro Potential in HER2-Positive Breast Cancer Imaging
by: Maria-Roxana Tudoroiu-Cornoiu, et al.
Published: (2025-06-01)

Affibodies as valuable tool to prevent β2m aggregation under lysosomal-like conditions
by: Cristina Visentin, et al.
Published: (2025-06-01)

Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation
by: Maryam Oroujeni, et al.
Published: (2024-04-01)

Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors
by: Maryam Oroujeni, et al.
Published: (2018-09-01)

Affibody-based targeting agent 131I-YZHER2: V2 for HER2-positive ovarian cancer xenografts
by: Hongyu Hu, et al.
Published: (2025-07-01)

The Use of a Non-Conventional Long-Lived Gallium Radioisotope <sup>66</sup>Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule
by: Maryam Oroujeni, et al.
Published: (2021-02-01)

Characterization of TMEM16F-Specific Affibodies and Their Cellular Effects
by: Eunyoung Kim, et al.
Published: (2025-08-01)

Albumin incorporation into recognising layer of HER2-specific magnetic nanoparticles as a tool for optimal targeting of the acidic tumor microenvironment
by: Olga A. Kolesnikova, et al.
Published: (2024-07-01)

Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3
by: Maryam Oroujeni, et al.
Published: (2022-08-01)

EGFR-antagonistic affibody-functionalized Pt-based nanozyme for enhanced tumor radiotherapy
by: Haijun Wang, et al.
Published: (2023-06-01)

Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart
by: Javad Garousi, et al.
Published: (2022-08-01)

Generation of human TMEM16F-specific affibodies using purified TMEM16F
by: Eunyoung Kim, et al.
Published: (2024-01-01)

Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma
by: Saidu Kamara, et al.
Published: (2024-11-01)

Computation-Aided Design of Albumin Affibody-Inserted Antibody Fragment for the Prolonged Serum Half-Life
by: Na Hyun Kwon, et al.
Published: (2022-08-01)

Stability Enhancement of a Dimeric HER2-Specific Affibody Molecule through Sortase A-Catalyzed Head-to-Tail Cyclization
by: Kristina Westerlund, et al.
Published: (2021-05-01)

Optimized method for fluorine-18 radiolabeling of Affibody molecules using RESCA
by: Francesco Lechi, et al.
Published: (2024-10-01)

Injection of Affibodies by a Self-Organizing Bacterial Syringe to Interfere with Intracellular Signaling
by: Thomas Müller, et al.
Published: (2025-09-01)

Melittin derived peptide-drug conjugate, M-DM1, inhibits tumor progression and induces effector cell infiltration in melanoma by targeting M2 tumor-associated macrophages
by: Chanmi Jeong, et al.
Published: (2023-04-01)

A novel HER2 targeting nanoagent self-assembled from affibody-epothilone B conjugate for cancer therapy
by: Xuelin Xia, et al.
Published: (2024-08-01)

Phage Display Affibodies Combined with AuNPs@Ru(bpy)<sub>3</sub><sup>2+</sup> for Ultra-Sensitive Electrochemiluminescence Detection of Abrin
by: Shuai Liu, et al.
Published: (2022-05-01)